SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Monday reported a loss of $42.5 million in its fourth quarter.

On a per-share basis, the Salt Lake City-based company said it had a loss of 47 cents. Earnings, adjusted for one-time gains and costs, came to 3 cents per share.

The results met Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was also for earnings of 3 cents per share.

The molecular diagnostic company posted revenue of $210.6 million in the period.

For the year, the company reported a loss of $127.3 million, or $1.41 per share. Revenue was reported as $837.6 million.

For the current quarter ending in March, Myriad expects its results to range from a loss of 8 cents per share to a loss of 4 cents per share.

The company said it expects revenue in the range of $196 million to $204 million for the fiscal first quarter.

Myriad expects full-year earnings in the range of 7 cents to 11 cents per share, with revenue ranging from $840 million to $860 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYGN at https://www.zacks.com/ap/MYGN